Read by QxMD icon Read

Transarterial Chemoembolization

Woohyung Lee, Ho-Seong Han, Soyeon Ahn, Yoo-Seok Yoon, Jai Young Cho, YoungRok Choi
BACKGROUND: The relationship between resection margin (RM) and recurrence of resected hepatocellular carcinoma (HCC) is unclear. METHODS: We reviewed clinical data for 419 patients with HCC. The oncologic outcomes were compared between 2 groups of patients classified according to the inflexion point of the restricted cubic spline plot. RESULTS: The patients were divided according to an RM of <1 cm (n = 233; narrow RM group) or ≥1 cm (n = 186; wide RM group)...
January 17, 2018: Digestive Surgery
Yusuke Matsui, Masahiro Horikawa, Younes Jahangiri Noudeh, John A Kaufman, Kenneth J Kolbeck, Khashayar Farsad
Background: The aim of the study was to evaluate the association between baseline Lipiodol uptake in hepatocellular carcinoma (HCC) after transarterial chemoembolization (TACE) with early tumor recurrence, and to identify a threshold baseline uptake value predicting tumor response. Patients and methods: A single-institution retrospective database of HCC treated with Lipiodol-TACE was reviewed. Forty-six tumors in 30 patients treated with a Lipiodol-chemotherapy emulsion and no additional particle embolization were included...
December 2017: Radiology and Oncology
Joseph D Morrison, Collin K Schlager, Amanda E Lee, Richard B van Breemen, Ron C Gaba
PURPOSE: We aimed to test the hypothesis that doxorubicin (DOX) survives thermal ablative heating in an ex vivo model of combined transarterial chemoembolization (TACE) and thermal ablation. METHODS: Fresh porcine psoas major muscle (3 samples, 15×10×3 cm) was submerged in aqueous DOX solution (60 µg/mL, 0.1 M) for 24 hours to passively saturate tissue. DOX-infused tissue was then dried and treated with microwave ablation (MWA) using a 2.45 GHz antenna at 65 W for 2, 5, and 10 minutes...
January 2018: Diagnostic and Interventional Radiology: Official Journal of the Turkish Society of Radiology
Nam Hee Kim, Taeheon Lee, Yong Kyun Cho, Byung Ik Kim, Hong Joo Kim
BACKGROUND AND AIM: To determine the impact of clinically evident portal hypertension (CEPH) on prognosis of hepatocellular carcinoma (HCC) patients with Child-Pugh A cirrhosis who underwent transarterial chemoembolization (TACE). METHODS: A retrospective data analysis was performed for a total of 388 treatment-naïve HCC patients with Child-Pugh A cirrhosis who underwent TACE as first-line treatment from January 2000 to June 2014. Cumulative occurrence rate of complete response (CR), progression free survival (PFS), and overall survival (OS) were compared between patients with CEPH and those without CEPH [esophageal/gastric varices or low platelet count (<100,000/mm3 ) associated with splenomegaly]...
January 3, 2018: Journal of Gastroenterology and Hepatology
Marco Biolato, Giulia Gallusi, Massimo Iavarone, Giuseppe Cabibbo, Simona Racco, Adriano De Santis, Cristina Della Corte, Marcello Maida, Adolfo Francesco Attili, Angelo Sangiovanni, Calogero Cammà, Giuseppe La Torre, Antonio Gasbarrini, Antonio Grieco
Prognostic ability of BCLC-B Subclassification in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Background and aims. A subclassification system for intermediate hepatocellular carcinoma (HCC) was recently proposed to optimize treatment allocation. The aim of this study was to assess the prognostic ability of that substaging proposal. PATIENTS AND METHODS: This is a retrospective multicenter cohort study including patients with intermediate HCC treated with transarterial chemoembolization (TACE)...
December 27, 2017: Annals of Hepatology
I-Chang Lin, Chi-Ming Tai, Chao-Ming Tseng
No abstract text is available yet for this article.
December 30, 2017: Digestive and Liver Disease
Yingshi Zhang, Fuhai Hui, Yue Yang, Haixiao Chu, Xiaochun Qin, Mingyi Zhao, Qingchun Zhao
Objective: To assess the comparative efficacy and safety of combination treatment with Compound Kushen Injection (CKI) and transarterial chemoembolization (TACE) in patients with advanced hepatocellular carcinoma (HCC) through a systematic review and network meta-analysis and to identify the best conditions for using CKI. Materials and Methods: We performed a network meta-analysis based on randomized controlled trials. We searched databases for studies published by August 2017...
December 5, 2017: Oncotarget
Ron C Gaba, Regina M Schwind, Sebastien Ballet
PURPOSE: To systematically review mechanism of action, pharmacokinetics (PKs), efficacy, and safety of ethiodized oil-based locoregional therapy (LRT) for liver cancer in preclinical models. MATERIALS AND METHODS: A MEDLINE search was performed from 1988 to 2016. Search terms included hepatocellular carcinoma (HCC), HCC, liver-cell carcinoma, liver, hepatic, hepatocarcinoma, transarterial or chemoembolization, TACE, animal, Lipiodol, Ethiodol, iodized oil, and/or poppy-seed oil...
December 28, 2017: Journal of Vascular and Interventional Radiology: JVIR
Tsutomu Tamai, Kotaro Kumagai, Haruka Sakae, Hiroka Onishi, Kazuaki Tabu, Eriko Tabu, Kaori Muromachi, Akiko Saishoji, Kohei Oda, Seiichi Mawatari, Akihiro Moriuchi, Kazuhiro Sakurai, Akio Ido
This prospective study aimed to estimate the efficacy of sorafenib therapy after transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (HCC). Between July 2011 and March 2013, 17 patients were enrolled, 11 of whom received sorafenib therapy. Patients who previously received TACE for HCC and whose disease progressed within a six-month period were given 400-800 mg sorafenib orally, once or twice daily, within the 3 weeks after a second TACE (sorafenib after TACE group). The response to treatment, time to progression (TTP), overall survival (OS), and adverse events (AEs) were recorded...
December 2017: Molecular and Clinical Oncology
Xiu-Ping Zhang, Kang Wang, Nan Li, Cheng-Qian Zhong, Xu-Biao Wei, Yu-Qiang Cheng, Yu-Zhen Gao, Han Wang, Shu-Qun Cheng
BACKGROUND: No consensus treatment has been reached for hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT). Hepatic resection (HR) and transarterial chemoembolization (TACE) have been recommended as effective options, but which is better remains unclear. This meta-analysis is to compare the effectiveness of HR and TACE for HCC with PVTT patients. METHODS: The PubMed, EMBASE, Cochrane Library, VIP, Wan Fang, and Sino Med databases were systematically searched for comparing HR and TACE treating PVTT...
December 28, 2017: BMC Cancer
Yutaka Yasui, Kaoru Tsuchiya, Masayuki Kurosaki, Takaya Takeguchi, Yuko Takeguchi, Mao Okada, Wan Wang, Yohei Kubota, Tomoyuki Goto, Yasuyuki Komiyama, Mayu Higuchi, Kenta Takaura, Tsuguru Hayashi, Hitomi Takada, Nobuharu Tamaki, Hiroyuki Nakanishi, Jun Itakura, Yuka Takahashi, Yasuhiro Asahina, Nobuyuki Enomoto, Yoshiro Himeno, Namiki Izumi
AIMS: Intermediate-stage hepatocellular carcinoma varies widely in tumor burden and liver function. This study aimed to clarify the importance of subclassification by the up-to-seven criteria in both clinical course and liver function deterioration in such patients. METHODS: We retrospectively analyzed 224 patients with Child-Pugh grade A who underwent initial transarterial chemoembolization for hepatocellular carcinoma. Tumor downstaging to within Milan criteria within 1 year and liver function worsening as Child-Pugh grade deterioration from A to B were analyzed...
December 26, 2017: Hepatology Research: the Official Journal of the Japan Society of Hepatology
Toshihiro Tanaka, Tetsuya Masada, Hideyuki Nishiofuku, Yasushi Fukuoka, Takeshi Sato, Shota Tatsumoto, Nagaaki Marugami, Shushi Higashi, Kimihiko Kichikawa
PURPOSE: To evaluate a pumping emulsification device that can improve the physiochemical properties and stability of lipiodol emulsion for conventional transarterial chemoembolization. MATERIALS AND METHODS: A pumping emulsification device constructed of a glass membrane with a hydrophobic surface with pore size of 50 μm in diameter was placed between two syringe adaptors. Epirubicin solutions were mixed with lipiodol with pumping exchanges using the emulsification device or a three-way cock...
December 15, 2017: European Radiology
Changfu Liu, Wenge Xing, Tongguo Si, Haipeng Yu, Zhi Guo
Objective: To investigate the efficacy and safety of combined therapy with apatinib and transarterial chemoembolization (TACE) for hepatocellular carcinoma with portal venous tumor thrombus (PVTT). Materials and Methods: We retrospectively analyzed 19 patients with hepatocellular carcinoma with PVTT who were treated with apatinib and TACE at a single center between January 2015 and January 2017. Clinical information on the patients was collected. Adverse events, overall survival, progression-free survival, objective response rate, and disease-control rate based on mRECIST criteria (American Association for the Study of Liver Diseases, 2008) were reviewed and evaluated...
November 21, 2017: Oncotarget
Hui Xie, Haipeng Yu, Shengtao Tian, Xueling Yang, Ximing Wang, Zhao Yang, Huaming Wang, Zhi Guo
Objective: To assess the comparative efficacy and safety of combination treatment with transarterial chemoembolization (TACE) for patients with unresectable hepatocellular carcinoma (HCC) through a systematic review and network meta-analysis and to identify what is the best combination treatment with TACE. Materials and Methods: A network meta-analysis was used to identify evidence from relevant randomized controlled trials. We searched databases for publications up to June 2017...
November 21, 2017: Oncotarget
Ji Hae Nahm, Hyungjin Rhee, Haeryoung Kim, Jeong Eun Yoo, Jee San Lee, Youngsic Jeon, Gi Hong Choi, Young Nyun Park
Background: Hepatocellular carcinomas (HCCs) expressing stemness markers are characterized by an aggressive behavior, which might be promoted by an altered tumor stroma. Transarterial chemoembolization (TACE) induces severe hypoxia, and its effect on stemness and tumor stroma of HCCs remains unclear. The purpose of this study was to evaluate the sequential changes of stemness and tumor stroma under TACE-induced hypoxia using biopsy and resection-matched HCCs. Methods: Forty-six biopsy and resection matched HCCs including 10 cases with and 36 cases without preoperative TACE were selected...
November 21, 2017: Oncotarget
Sunfu Fan, Bingqi Yu, Xinbao Wang
PURPOSE: To clarify the necessity of prophylactic transarterial chemoembolization (pTACE) after radical resection for small hepatocellular carcinoma (sHCC) (<3.0 cm) and identify prognostic determinants. MATERIALS AND METHODS: Consecutive 161 patients with sHCC in Zhejiang Cancer Hospital from May 2009 to May 2014 were retrospectively studied. In these patients, 87 patients only received radical resection alone (control group), while other 74 patients received pTACE after radical resection (pTACE group)...
2017: Journal of Cancer Research and Therapeutics
Jun Zhou, Ying Liu, Zhizhong Ren, Yuewei Zhang, Ming Zhang
OBJECTIVE: The purpose of this investigation is to present a preliminary clinical experience in transarterial chemoembolization (TACE) with gelatin sponge microparticles (GSMs) for barcelona clinic liver cancer (BCLC) Stage C and large hepatocellular carcinoma (HCC) patients in China. MATERIALS AND METHODS: Between August 2009 and August 2012, 20 BCLC Stage C HCC patients with tumor size ≥5 cm undergoing GSMs-TACE were retrospectively analyzed. Tumor response was evaluated using modified response evaluation criteria in solid tumors (mRECIST) with enhanced magnetic resonance/computed tomography imaging performed 4-6 weeks after each GSMs-TACE procedure...
2017: Journal of Cancer Research and Therapeutics
Charlotte E Costentin, Cristina R Ferrone, Ronald S Arellano, Suvranu Ganguli, Theodore S Hong, Andrew X Zhu
Background: Tumoral macrovascular invasion (MVI) of hepatic and/or portal vein branches is a common phenomenon in hepatocellular carcinoma (HCC) and is associated with poorer prognosis when compared to HCC without MVI. Summary: Current international guidelines for the management of HCC recommend sorafenib as the only treatment option in case of MVI. Despite guideline recommendations, several alternative options have been tested to manage HCC with MVI: surgery, transarterial chemoembolization, external or internal radiation, hepatic arterial infusion chemotherapy, percutaneous treatment, cryotherapy, or the combination of two or more of these strategies, with or without sorafenib...
November 2017: Liver Cancer
Clarence Yen, Rohini Sharma, Lorenza Rimassa, Tadaaki Arizumi, Dominik Bettinger, Huay Yee Choo, Tiziana Pressiani, Michela E Burlone, Mario Pirisi, Laura Giordano, Anisa Abdulrahman, Masatoshi Kudo, Robert Thimme, Joong Won Park, David James Pinato
Background: Level I evidence supports the use of sorafenib in patients with Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma, where heterogeneity in efficacy exists due to varying clinicopathologic features of the disease. Aim: We evaluated whether prior treatment with curative or locoregional therapies influences sorafenib-specific survival. Methods: From a prospective data set of 785 consecutive patients from international specialist centres, 264 patients (34%) were treatment naïve (TN) and 521 (66%) were pre-treated (PT), most frequently with transarterial chemoembolization (n = 413; 79%)...
November 2017: Liver Cancer
Carla Rognoni, Oriana Ciani, Silvia Sommariva, Rosanna Tarricone
AIM: We evaluated two treatment sequences, transarterial radioembolization followed by transarterial chemoembolization and possibly sorafenib (=TTS) versus transarterial radioembolization followed by sorafenib alone (=TS), to identify the most cost-effective pathway to treat intermediate-stage hepatocellular carcinoma from the Italian healthcare system perspective. MATERIALS & METHODS: A Markov model was developed to project costs and health outcomes for TTS and TS over a lifetime horizon...
December 12, 2017: Journal of Comparative Effectiveness Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"